Introduction
Ocular neovascularization is the key pathobiological feature of diseases like proliferative diabetic retinopathy (PDR), retinopathy of prematurity (ROP), and wet agerelated macular degeneration (AMD), which together are major causes of blindness (Campochiaro, 2013) . In PDR and ROP, abnormal blood vessels grow in and on the retina, while in wet AMD, neovessels grow from the pigmented, subretinal choroid layer into the retina. In all cases, neovessels disrupt retinal architecture and can hemorrhage, leading to blindness. Although the exact stimuli promoting neovascularization are not always well characterized, hypoxia and inflammation both play crucial roles. The currently used, FDA approved pharmacological treatments for these diseases are all biologics targeting the vascular endothelial growth factor (VEGF) signaling pathway, such as ranibizumab and aflibercept (Prasad et al., 2010) . Although these therapeutic agents have been very successful, significant proportions of patients are resistant and refractory (Lux et al., 2007; Falavarjani and Nguyen, 2013) . Moreover, serious side effects including hemorrhage and endophthalmitis are possible. Therefore, development of novel therapeutic approaches targeting other signaling pathways is crucial.
One such potential target is the reduction-oxidation factor 1-apurinic/apyrimidinic endonuclease 1 (Ref-1/APE1), an intracellular signaling nexus with important roles in transducing proangiogenic stimuli. This bifunctional protein has an endonuclease role essential for base excision repair (APE1), while the Ref-1 activity is a redox-sensitive transcriptional activator (Shah et al., 2017) . Ref-1 redox signaling is a highly regulated process that reduces oxidized cysteine residues in specific transcription factors as part of their transactivation 7 Evans et al., 2000; Lando et al., 2000; Nishi et al., 2002; Seo et al., 2002; Li et al., 2010; Fishel et al., 2011; Cardoso et al., 2012; Kelley et al., 2012; Luo et al., 2012; Zhang et al., 2013; Fishel et al., 2015; Logsdon et al., 2016) . This redox signaling affects numerous transcription factors including HIF-1α, NF-κB, and others. The regulation of HIF-1α and NF-κB are particularly relevant to angiogenesis and eye diseases (Evans et al., 2000; Nishi et al., 2002; Seo et al., 2002; Fishel et al., 2011; Cardoso et al., 2012; Fishel et al., 2015; Logsdon et al., 2016 (Luo et al., 2008; Fishel et al., 2010; Su et al., 2011; Cardoso et al., 2012; Luo et al., 2012; Zhang et al., 2013; Fishel et al., 2015) .
Pharmacologic inhibition of Ref-1 via APX3330 blocks Ref-1 redox activity on NF-κB,
HIF-1α, AP-1, and STAT3, decreasing transcription factor binding to DNA in vitro (Fishel et al., 2011; Jedinak et al., 2011; Luo et al., 2012) . APX3330 has entered Phase I clinical trials for safety and recommended Phase II dose (RP2D) in cancer patients (NCT03375086); however, the safety and dose administration of APX3330 have been previously established by Eisai Inc. through a prior development program for a noncancer, Hepatitis C indication that evaluated the preclinical toxicology, Phase I and 8 Phase II safety and clinical profile in more than 400 non-cancer patients (Shah et al., 2017) .
Ref-1/APE1 is highly expressed during retinal development, and in retinal pigment epithelium (RPE) cells, pericytes, choroidal endothelial cells and retinal endothelial cells (Chiarini et al., 2000; Jiang et al., 2011; Li et al., 2014a) . More generally, Ref-1 is frequently upregulated in regions of tissues in which inflammation is present (Zou et al., 2009; Kelley et al., 2010) . APX3330 was previously shown to block in vitro angiogenesis, as evidenced by proliferation, migration, and tube formation of retinal and choroidal endothelial cells (Jiang et al., 2011; Li et al., 2014b) . Indeed, APX3330 delivered intravitreally (directly into the eye) reduced neovascularization in the very low density lipoprotein receptor (VLDLR) knockout mouse model of retinal neovascularization (Jiang et al., 2011) , and also in laser-induced choroidal neovascularization (L-CNV) (Li et al., 2014b) , the most widely used animal model that recapitulates features of wet AMD (Grossniklaus et al., 2010) .
While the lead clinical candidate is effective in preclinical cancer studies, we also sought novel, second generation Ref-1 inhibitors that would have increased efficacy in antiangiogenic and anti-inflammatory transcription factor (NF-κB, HIF-1α) inhibition, as well as new chemical properties. We present here the synthesis of APX3330 derivatives APX2009 (reported previously as a neuroprotective agent ), and APX2014 (reported here for the first time (Kelley and Wikel, 2015) ). We go on to show that these compounds have antiangiogenic activity against retinal and choroidal endothelial cells both in culture and in an ex vivo choroidal sprouting model. Finally, we 9 show that APX2009 is an effective systemic treatment for L-CNV, establishing these compounds as leads for further development for neovascular eye diseases.
Materials and Methods
Synthetic Methods. The compounds were synthesized by Cascade Custom Chemistry (Eugene, OR) and provided by Apexian Pharmaceuticals. In summary ( Fig.   1A ), the common intermediate iodolawsone (2-iodo-3-hydroxy-1,4-naphthoquinone (1); available from Cascade Custom Chemistry) was treated with 2-propylacrylic acid (2), with oxalyl chloride and the corresponding amine, and with sodium methoxide in methanol to yield (E)-N,N-diethyl-2-((3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2yl)methylene)pentanamide (6a; APX2009), and (E)-N-methoxy-2-((3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methylene)pentanamide (6b; APX2014). Full synthetic details can be found in the Supplemental Methods. APX3330 was synthesized as described (Luo et al., 2008) .
Electrophoretic mobility shift assays (EMSA). These assays were performed as previously described (Luo et al., 2008; Kelley et al., 2011; Su et al., 2011; Luo et al., 2012; Zhang et al., 2013) . Briefly, an increasing amount of APX3330, APX2009 or APX2014 was preincubated with purified Ref-1 protein in EMSA reaction buffer for 30 min. The EMSA assay was performed using the AP-1 target DNA sequence and AP-1 protein.
Cells. Primary human retinal microvascular endothelial cells (HRECs) were obtained from Cell Systems, Inc. (Kirkland, WA), while the Rf/6a macacque choroidal endothelial cell line was obtained from ATCC (Manassas, VA). Cells were maintained as described (Basavarajappa et al., 2017) , re-ordered at least annually, and regularly assessed for mycoplasma contamination.
In vitro cell proliferation assay. Endothelial cell proliferation was assessed as described previously (Basavarajappa et al., 2014; Basavarajappa et al., 2017) . Briefly, 2.5×10 3 cells were seeded in 100 μL of growth medium and plated in each well of 96well clear-bottom black plates and incubated for 24 h. APX2009, APX2014, or DMSO vehicle (DMSO final concentration = 1%) was added, and the plates were incubated for 24-48 h at 37°C and 5% CO2. AlamarBlue reagent (11.1 μL) was added to each well of the plate and 4 h later fluorescence readings were taken at excitation and emission wavelengths of 560 nm and 590 nm, respectively, using a Synergy H1 plate reader (BioTek, Winooski, VT). GI50 was calculated using GraphPad Prism v. 7.0.
In vitro cell migration assay. Endothelial cell migration was monitored as described before (Basavarajappa et al., 2014; Basavarajappa et al., 2017) . Briefly, HRECs and Rf/6a were grown until confluency in 12-well plates. Using a sterile 10-μL micropipette tip, a scratch wound was made across the center of each well and fresh complete media containing DMSO or different concentrations of APX2009 or APX2014 compounds were added to the wells (DMSO final concentration = 1%). Wells were imaged via digital brightfield microscopy at different time points, and the number of migrated cells into the scratched area was manually counted.
In vitro Matrigel tube formation assay. The ability of HRECs and Rf/6a cells to form tubes in vitro was monitored as described before (Basavarajappa et al., 2014; Basavarajappa et al., 2017) . Briefly, 1.5×10 4 cells in 100 μL of growth medium containing DMSO or APX compounds were added to each well of a 96-well plate that was pre-coated with 50 μL per well of Matrigel basement membrane (DMSO final concentration = 1%). Brightfield digital micrographs of each well at different time points were taken to measure the in vitro tube formation using the Angiogenesis Analyzer (Wenzel et al., 2015) . Mice were anesthetized for all procedures by intraperitoneal injections of 90 mg/kg ketamine hydrochloride and 5 mg/kg xylazine, with intraperitoneal atipamezole reversal (1 mg/kg). Treatments were randomly assigned by cage.
Choroidal sprouting assay. Ex vivo Choroidal sprouting was assessed as described previsouly (Sulaiman et al., 2016; Basavarajappa et al., 2017) . Briefly, choroid-sclera was dissected from 7 to 8 week old mouse eyes and pieces were embedded in Matrigel (growth factor reduced) and grown in EGM-2 medium containing antibiotics for 72 h to allow sprouting to initiate. The indicated concentrations of APX2009 and APX2014 compounds (in DMSO, final DMSO concentration 0.5 and 0.2%, respectively) were added and growth allowed to proceed for 48 h. Images were taken and growth was quantified by measuring the distance from the edge of the choroidal piece to the growth front in four directions per sample using ImageJ software.
Laser-induced choroidal neovascularization. L-CNV was induced as described previously (Sulaiman et al., 2015; Sulaiman et al., 2016; Basavarajappa et al., 2017) . Studies were powered to have an 80% chance of detecting effect size differences of 50%, assuming 30% variability, α = 0.05. Briefly, pupils of anesthetized mice were dilated with 1% tropicamide (Alcon Laboratories Inc., Forth Worth, TX) and lubricated with hypromellose ophthalmic demulcent solution (Gonak) (Akorn, Lake Forest, IL). A coverslip was used to allow viewing of the posterior pole of the eye. Three burns of a 532 nm ophthalmic argon green laser coupled with a slit lamp (50 μm spot size, 50 ms duration, and 250 mW pulses) were delivered to each 3, 9, and 12 o'clock position, two-disc diameters from optic disc. The bubbling or pop sensed after laser photocoagulation was considered as the successful rupture of Bruch's membrane.
Lesions in which bubbles were not observed were excluded from the study. To assess the antiangiogenic activity of APX3330, the mice were i.p. injected with compound (50 mg/kg body weight), twice daily, five days on/two days off, as used previously in vivo (Fishel et al., 2011; Lou et al., 2014; Biswas et al., 2015) . Vehicle was 4% Cremophor:ethanol (1:1) in PBS. For APX2009, doses were 12.5 mg/kg or 25 mg/kg body weight, twice daily until 14 days of laser treatment unless otherwise indicated.
Vehicle was propylene glycol, Kolliphor HS15, Tween 80 (PKT) (McIlwain et al., 2017) .
Mice were weighed daily.
In vivo imaging. Optical coherence tomography (OCT) was performed in L-CNV mice as described previously (Sulaiman et al., 2016) , at the indicated times using the Micron III intraocular imaging system (Phoenix Research Labs, Pleasanton, CA). Briefly, before the procedure, eyes of anesthetized mice were dilated with 1% tropicamide solution (Alcon, Fort Worth, TX) and lubricated with hypromellose ophthalmic demulcent solution (Gonak) (Akorn, Lake Forest, IL, USA). Mice were then placed on a custom heated stage that moves freely to position the mouse eye for imaging. Several horizontal and vertical OCT images were taken per lesion.
Fluorescein angiography was performed 14 days post laser by intraperitoneal injection of 50 μL of 25% fluorescein sodium (Fisher Scientific, Pittsburgh, PA).
Fundus images were taken using the Micron III system and Streampix software.
Immunofluorescence. Mouse eyes were harvested 14 days after L-CNV induction. The eyes were enucleated and fixed in 4% paraformaldehyde/PBS overnight.
The anterior segment, lens, and retina were removed, and the posterior eye cups were prepared for choroidal flat mounts. The posterior eye cups were washed with PBS and permeabilized in blocking buffer containing 0.3% Triton X-100, 5% bovine serum albumin (BSA) in PBS for two hours at 4°C. The eye cups were then double stained for vasculature with rhodamine-labeled Ricinus communis agglutinin I (Vector Labs, Burlingame, CA) and Alexa Fluor TM 488 conjugated-Isolectin B4 from Griffonia simplicifolia (GS-IB4) (Molecular Probes, Thermo Fisher Scientific) at 1:250 dilution in buffer containing 0.3% Triton X-100, 0.5% BSA in PBS for 16-20 hours at 4°C. After antibody incubation, whole mounts were washed three times with PBS for 15 mins each step at 4°C with 0.1% Triton X-100. After washing, choroidal flatmounts were mounted in aqueous mounting medium (VectaShield; Vector Laboratories, Inc.) and coverslipped for observation by confocal Z-stack imaging (LSM 700, Zeiss, Thornwood, NY) to estimate lesion volume. The sum of the stained area in each optical section, multiplied by the distance between sections (3 μm), gave the CNV lesion volume and lesion volume was quantified using ImageJ software. Lesions were only included for analysis if they met quality control standards as published (Poor et al., 2014) . All lesions in an eye were averaged to represent a single n.
Statistical analyses. Statistical analyses were performed with GraphPad Prism 7 software. One-way ANOVA was used with Dunnett's post hoc test for migration, tube formation, and choroidal sprouting experiments. Unpaired Student's t-test was used for the APX3330 in vivo experiment. One-way ANOVA was used with Tukey's post hoc test for L-CNV analysis in APX2009 in vivo experiments, while repeated measures two-way ANOVA was used to compare body weights between treatments and over time. Twosided p values < 0.05 were considered statistically significant.
Results

Novel Ref-1 inhibitors are more potent than APX3330 in blocking binding of
AP-1 DNA binding. We synthesized APX2009 (6a) and APX2014 (6b) (Fig. 1A) and demonstrated that both compounds had enhanced inhibition of Ref-1-induced transcription factor binding to DNA compared to APX3330 (7) (Fig. 1B) , while having substantially different physiochemical properties. The new compounds have lower molecular weights, and lack the carboxylate group and long alkyl chain of APX3330.
The new compounds also have significantly reduced lipophilicity as determined by computer based calculation of their clogP values, APX3330 = 4.5, APX2009 = 2.7, and APX2014 = 1.9.
APX2009 and APX2014 block endothelial cell proliferation. Endothelial cell proliferation with increased survival supports the cells that make up new blood vessels, leading to angiogenesis. As an initial test of the antiangiogenic potential of our novel Ref-1 inhibitors, we assessed their ability to inhibit the proliferation of HRECs and Rf/6a choroidal endothelial cells (Fig. 2) . Both compounds dose-dependently blocked proliferation of both cell types in an alamarBlue assay, with APX2014 5-to 10-fold more potent than APX2009. Primary HRECs were more sensitive to both compounds than the Rf/6a choroidal cell line, as seen with other antiangiogenic compounds (Basavarajappa et al., 2017) .
APX2009 and APX2014 block endothelial cell migration. Neovascularization
involves an array of coordinated events, including extracellular matrix degradation, cell migration, cell proliferation, and morphogenesis of endothelial cells. To know the effect of APX2009 and APX2014 compounds on endothelial cell migration, a scratch-wound assay was performed. (Fig. 3; Supplemental Figs. 1 & 2) . Both compounds again were dose-dependently and significantly effective here, without causing obvious cytotoxicity over the short time course of these assays.
APX2009 and APX2014 block endothelial cell tube formation. Endothelial cells organize and form capillary-like structures upon plating on an extracellular matrix such as Matrigel. The organization of endothelial cells into a three-dimensional network of tubes is essential for angiogenesis. As such, the Matrigel tube formation assay is a good in vitro predictor of angiogenic potential in vivo. In this assay, both APX2009 and APX2014 inhibited tubule formation markedly, at concentrations lower than those required for inhibiting migration alone, strongly indicative of antiangiogenic activity (Fig. 4; Supplemental Figs. 3 & 4) .
APX2009 and APX2014 block angiogenesis ex vivo.
As a further test of activity, we employed a choroidal sprouting assay using murine choroidal explants to test the effect of the APX compounds in a complex microvascular bed in tissues (Fig. 5 ).
In this assay, choroidal cells grow out of the choroidal tissue piece into a surrounding
Matrigel matrix. Both compounds significantly reduced sprouting, with APX2014 remaining more potent. At 10 µM, APX2009 reduced sprouting by ~70% compared to control (Fig. 5A, B) , while at 1 µM (the highest concentration tested), APX2014 reduced sprouting by ~60% compared to control (Fig. 5C, D) .
Systemic Ref-1 inhibition with parent compound APX3330 can prevent L-
CNV. Previous efforts to attenuate ocular neovascularization by Ref-1 inhibition using APX3330 relied on intravitreal delivery of compound (Jiang et al., 2011; Li et al., 2014a; Li et al., 2014b) . Although this is the delivery route of the standard-of-care anti-VEGF biologics and ensures that the drug gets to the right place, in humans it is laborintensive, causes patient discomfort, and incurs a risk of potentially vision-threatening endophthalmitis (Day et al., 2011) . Thus, we explored if systemic (intraperitoneal) administration of Ref-1 inhibitors could offer an alternative route of therapy for L-CNV.
As a proof-of-concept, we tested i.p. injections of the first-generation Ref-1 inhibitor APX3330 (7) delivered 50 mg/kg twice daily, 5 days on/two days off, for two weeks. This dosing regimen was chosen as it was previously successful and non-toxic for preclinical tumor studies (Fishel et al., 2011; Lou et al., 2014; Biswas et al., 2015) . Animals treated with APX3330 displayed significantly reduced L-CNV volume (Fig. 6) .
Systemic administration of more potent derivative APX2009 reduces L-CNV significantly. Given that APX3330 reduced L-CNV with systemic adminstration, we explored if similar effects could be observed with our second-generation Ref-1 inhibitors. We chose APX2009 for this experiment as it had previously been safely dosed in animals . We used two dosage regimens previously employed, 12.5 or 25 mg/kg twice daily for two weeks. The lower dose did not reduce L-CNV, but the 25 mg/kg dose had a marked effect (Fig. 7) . This was qualitatively evident by OCT imaging on Day 7, and even more substantial on Day 14 (Fig. 7A ). In addition, reduced fluorescein leakage was seen in lesions by fluorescein angiography at Day 14 ( Fig. 7B) . Finally, L-CNV lesion volume assessed by ex vivo staining with agglutinin ( Fig. 7C ) and isolectin B4 (Supplemental Fig. 5) , was reduced by 25 mg/kg APX2009 approximately four-fold compared to vehicle (Fig. 7D ). (Forsythe et al., 1996) . In retinal pigment epithelial cells, APX3330 reduced both NF-κB and HIF-1α activity, with a concomitant reduction in VEGF expression (Li et al., 2014a; Li et al., 2014b) . Additionally, APX3330 treatment of stroke in type one diabetes mellitus rats significantly decreased total vessel density and VEGF expression (Yan et al., 2018) . However, the exact transcription factors modulated by Ref-1 inhibition in the context of ocular neovascularization remain to be determined.
Discussion
We did not observe obvious intraocular or systemic toxicity of the two compounds tested in vivo (APX3330 and APX2009), nor did we see substantial cell death in migration, tube formation, and choroidal sprouting assays. These findings are consistent with the excellent safety profile for APX3330 in humans (Shah et al., 2017) .
Nonetheless, ocular toxicity of the new compounds and intraocular pharmacokinetics remain to be thoroughly examined.
A well-tolerated, systemic drug therapy has significant potential for treatment of neovascular eye diseases. The existing approved drugs are all biologics requiring intravitreal injection in the context of an ophthalmologist's clinic. An orally bioavailable 20 drug (as with APX3330) could be administered at home, potentially as a once daily pill.
The tradeoff for such a therapy would be much more frequent dosing than that required for intravitreal injections (monthly or less), and more substantial systemic exposure than that seen with intravitreal therapies. But given the strong safety profile of inhibitors, this approach is feasible. Moreover, patient and healthcare system costs might be significantly lower with such a therapy, as office visits and injection procedures could be reduced. 
